XML 23 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
Total
6.50% Convertible Senior Notes Due 2024
August 2019 Bonds
Preferred stock
Common stock
Common stock
6.50% Convertible Senior Notes Due 2024
Common stock
August 2019 Bonds
Additional paid-in capital
Additional paid-in capital
6.50% Convertible Senior Notes Due 2024
Additional paid-in capital
August 2019 Bonds
Accumulated deficit
Accumulated other comprehensive income (loss)
Non- controlling interest
Beginning balance (in shares) at Dec. 31, 2018       23 97,225,810                
Beginning balance at Dec. 31, 2018 $ 87,032,407     $ 0 $ 97,226     $ 707,794,215     $ (620,426,436) $ (528,867) $ 96,269
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Issuance of common stock for cash, net of capital raising related expenses (in shares)         3,340,678                
Issuance of common stock for cash, net of capital raising related expenses 9,089,009       $ 3,340     9,085,669          
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)         794,546                
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (780,405)       $ 795     (781,200)          
Equity component of issuance of convertible notes 15,752,698             15,752,698          
Stock-based compensation 10,901,320             10,795,403         105,917
Acquisition of non-controlling interest in Geneos, net 2,960,131                       2,960,131
Net loss attributable to common stockholders (120,551,777)                   (119,359,219)   (1,192,558)
Unrealized gain/loss on short-term investments, net of tax 1,001,475                     1,001,475  
Foreign currency translation 0                        
Ending balance (in shares) at Dec. 31, 2019       23 101,361,034                
Ending balance at Dec. 31, 2019 5,404,858     $ 0 $ 101,361     742,646,785     (739,785,655) 472,608 1,969,759
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Issuance of common stock for cash, net of capital raising related expenses (in shares)         66,064,886                
Issuance of common stock for cash, net of capital raising related expenses 454,486,400       $ 66,065     454,420,335          
Conversion of preferred stock/senior notes to common stock (in shares)       (14) 5,147 11,535,660 4,962,364            
Conversion of preferred stock/senior notes to common stock 0 $ 43,694,386 $ 102,671,310   $ 5 $ 11,536 $ 4,961 (5) $ 43,682,850 $ 102,666,349      
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)         2,922,402                
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments 8,241,624       $ 2,923     8,238,701          
Stock-based compensation 15,647,523             15,655,585         (8,062)
Acquisition of non-controlling interest in Geneos, net 2,379,969                       2,379,969
Deconsolidation of Geneos (3,181,640)                       (3,181,640)
Net loss attributable to common stockholders (167,474,914)                   (166,411,157)   (1,063,757)
Dissolution of majority-owned subsidiary VGX Animal Health, Inc. 0             96,269         (96,269)
Unrealized gain/loss on short-term investments, net of tax (755,963)                     (755,963)  
Foreign currency translation 27,205                     27,205  
Ending balance (in shares) at Dec. 31, 2020       9 186,851,493                
Ending balance at Dec. 31, 2020 461,140,758     $ 0 $ 186,851     1,367,406,869     (906,196,812) (256,150) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Issuance of common stock for cash, net of capital raising related expenses (in shares)         27,310,341                
Issuance of common stock for cash, net of capital raising related expenses 209,441,410       $ 27,310     209,414,100          
Conversion of preferred stock/senior notes to common stock (in shares)             1,009,450            
Conversion of preferred stock/senior notes to common stock     $ 4,377,892       $ 1,009     $ 4,376,883      
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)         2,211,603                
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments 2,057,393       $ 2,212     2,055,181          
Stock-based compensation 26,336,764             26,336,764         0
Net loss attributable to common stockholders (303,658,710)                   (303,658,710)   0
Unrealized gain/loss on short-term investments, net of tax 4,048                     4,048  
Foreign currency translation (30,134)                     (30,134)  
Ending balance (in shares) at Dec. 31, 2021       9 217,382,887                
Ending balance at Dec. 31, 2021 $ 399,669,421     $ 0 $ 217,382     $ 1,609,589,797     $ (1,209,855,522) $ (282,236) $ 0